Retatrutide Injection 10 mg is a weight-loss medication that's in development. It works by acting like three gut hormones that help balance appetite and metabolism. The core innovation of retatrutide lies in its unique triple receptor agonist mechanism. As a 39-amino acid synthetic peptide, its molecular design achieves a 6-day half-life through succinyl-diacetyl coupling, enabling once-weekly injections. GLP-1 receptor activation: Suppresses appetite, delays gastric emptying, and promotes insulin secretion, establishing the foundation for weight loss and glycemic control. GIP receptor activation: Enhances insulin sensitivity, regulates lipid metabolism, and optimizes fat distribution. Glucagon receptor activation: Increases energy expenditure and fat oxidation, reduces hepatic fat accumulation, and promotes lipolysis. This triple-target synergy forms a closed-loop mechanism of "appetite suppression-metabolic acceleration-organ protection." Preclinical studies demonstrate that triple activation can improve energy metabolism efficiency by over 30%, reduce adipose tissue by up to 83%, while preserving lean body mass and avoiding muscle loss associated with traditional weight loss approaches.
Our Product Form
Retatrutide COA
 |
||
| Certificate of Analysis | ||
| Compound name | Retatrutide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 2381089-83-2 | |
| Quantity | 55.0g | |
| Packaging standard | 10g/bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202510090025 | |
| MFG | Oct 9th 2025 | |
| EXP | Oct 8th 2028 | |
| Structure | N/A | |
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.35% |
| Loss on drying | ≤1.0% | 0.26% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.39% |
| Total microbial count | ≤750cfu/g | 80 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 400ppm |
| Storage | Store in a sealed, dark, and dry place below 2-8°C | |
|
|
||
Drug Overview and Mechanism Innovation
Retatrutide, the world's first triple receptor agonist targeting GLP-1, GIP, and glucagon, delivers revolutionary weight loss effects through its 10mg injectable formulation by activating three metabolism-related receptors.
This 39-amino acid drug molecule features a C20 fatty acid modification that extends its half-life to 6 days, enabling once-weekly subcutaneous injections.
Its triple mechanism forms a closed-loop system of "appetite suppression-metabolic acceleration-organ protection": GLP-1 receptor activation delays gastric emptying and promotes insulin secretion; GIP receptor activation enhances insulin sensitivity and regulates lipid metabolism; glucagon receptor activation promotes lipolysis and energy expenditure.
This synergistic effect achieved an average weight loss of 24.2% in Phase II trials, approaching the efficacy of gastric bypass surgery, while simultaneously improving multidimensional metabolic indicators including blood glucose, lipids, blood pressure, and hepatic fat deposition.
Precision Strategies for Indication Screening
According to the latest medical consensus, Retatrutide is primarily indicated for patients with simple obesity (BMI ≥ 30) or those with BMI ≥ 27 who also have complications such as metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, or obstructive sleep apnea. This selection criterion is based on Phase III TRIUMPH-4 trial data, which demonstrated significantly lower discontinuation rates in severely obese patients (baseline BMI ≥35) compared to the lower BMI group, indicating greater tolerability and benefit in high-BMI populations. In clinical practice, multidisciplinary assessment is required to confirm indications, including:
Precise measurement and dynamic monitoring of body mass index
Assessment of metabolic syndrome components (abdominal obesity, hyperglycemia, hypertension, hypertriglyceridemia, low HDL)
Complication screening (liver/kidney function, bone density, ECG, sleep monitoring)
Psychological assessment and behavioral pattern analysis
Special populations require individualized evaluation: Elderly patients necessitate consideration of muscle mass and fall risk; those with hepatic or renal impairment require dose adjustment; cardiovascular disease patients require monitoring of heart rate and blood pressure changes.
Scientific Pathway for Dose Titration
01
The dose titration strategy of initiating at 2mg and increasing by 2mg every 4 weeks has been validated through Phase II/III clinical trials, effectively balancing efficacy and safety. This strategy is designed based on pharmacokinetic and pharmacodynamic characteristics:
The target dose is individualized based on efficacy and tolerability (typically 8-12mg).
Dose adjustments should follow an "Observe-Evaluate-Adjust" cycle:
Monitor gastrointestinal reactions within 48 hours during the initiation phase.
02
During the escalation phase, assess tolerance at each dose increment
During the maintenance phase, periodically evaluate efficacy and safety
Adjust titration speed in special cases: Extend intervals for gastrointestinal-sensitive patients; shorten cycles for those with insufficient response. Note that doses exceeding 12mg show no additional benefit but increase adverse reaction risk.
Evidence-Based Analysis of Long-Term Efficacy and Weight Rebound After Discontinuation
Long-term follow-up data indicate that retatrutide maintains stable weight loss effects during continuous treatment, but weight rebound occurs after discontinuation.
At the 12-week follow-up after the 68-week treatment period, patients who discontinued therapy experienced an average weight regain of 8%-10%, significantly lower than that observed with semaglutide (15%-20%) and tirzepatide (12%-18%).
Maintenance regimens combining lifestyle interventions with drug therapy effectively reduce the extent of rebound.
Regarding muscle mass preservation, while retatrutide promotes lipolysis through glucagon receptor activation, the risk of muscle loss warrants attention.
Recent studies indicate that combining retatrutide with muscle-targeted drugs (e.g., bimagrumab) may achieve dual effects of fat loss and muscle gain.
Safety Profile and Risk Management Strategies
Common adverse reactions: Gastrointestinal reactions (nausea, diarrhea, vomiting) occur in 60%-80% of cases, predominantly during dose escalation. These can be mitigated through a stepwise dose-increase strategy.
Cardiovascular Effects: Heart rate increases by 5-10 beats/min, systolic blood pressure decreases by 5-15 mmHg. Monitoring is required for patients with cardiovascular disease.
Metabolic Abnormalities: Elevated liver enzymes (ALT/AST) occur in 3%-5% of cases, mostly mild and reversible; renal function parameters remain stable with no significant deterioration observed.
Neurological Effects: Sensory abnormalities occur in 8%-20% of cases, mostly mild and reversible upon discontinuation.
Risk management requires a tiered approach: mild adverse reactions are managed through dose adjustment and symptomatic treatment; moderate reactions necessitate temporary discontinuation and evaluation; severe reactions require permanent discontinuation and initiation of emergency protocols. Special populations (elderly, patients with hepatic/renal impairment, cardiovascular disease) require individualized dose titration.
Application
Retatrutide Injection 10 mg pioneers a new era in obesity treatment through its triple receptor activation mechanism, offering encouraging surgical-level weight loss effects and multi-organ protective potential.
However, transitioning from laboratory research to clinical application requires overcoming multiple hurdles, including safety validation, accessibility optimization, and long-term risk management.
Looking ahead, with the comprehensive release of Phase III data and expanded indications, retatrutide holds promise as a cornerstone therapy for obesity and related metabolic disorders.
Yet its true value will be realized only through scientifically informed regulation and prudent application. As experts note: "There is no perfect drug, only scientifically sound treatment strategies." Retatrutide's ultimate mission is to restore weight loss to its health-centered essence-not a numbers game.
In the field of obesity treatment, retatrutide-the world's first triple receptor agonist targeting GLP-1, GIP, and glucagon-is expanding its applications as Phase III clinical trials progress and real-world data accumulates. As of January 2026, retatrutide has completed its global multicenter Phase III study and entered the regulatory approval phase.
Its application scope has expanded from simple obesity to the management of multiple conditions including metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease.
This forms a comprehensive treatment strategy centered on "weight loss as the foundation and multi-organ protection as the core.
Frequently Asked Questions
What is the use of retatrutide 10mg?
+
-
Retatrutide is being developed to target multiple metabolic conditions, with its primary uses in obesity management, type 2 diabetes, and fatty liver disease.
What happens after taking retatrutide?
+
-
In our meta-analysis, a higher rate of gastrointestinal-related adverse events, particularly nausea, vomiting, and constipation, in addition to hypersensitivity events was found in patients treated with retatrutide.
How fast will I lose weight on retatrutide?
+
-
One of the standout features of retatrutide is the rapid onset of its weight-loss effects. In the phase 2 trial, participants began experiencing notable reductions in body weight as early as 24 weeks, with the higher-dose groups (8 mg and 12 mg) demonstrating the most pronounced changes.
Is retatrutide better than Ozempic?
+
-
While retatrutide mimics three hormones to support weight loss and blood sugar levels, Ozempic only mimics one. Retatrutide also appears to support more significant weight loss than Ozempic. Research suggests that Ozempic supports an average weight loss of around 6 kg after 40 weeks.
How quickly does retatrutide start working?
+
-
Retatrutide tends to start working within 2 to 4 weeks. In a Phase 2 study, average weight loss in the first four weeks was about 2–5%, depending on the dose
Hot Tags: retatrutide injection 10 mg, China retatrutide injection 10 mg manufacturers, suppliers, AOD 9604 Capsules, AOD 9604 Injection, Retatrutide Injection 10 Mg, Semaglutide Spray, SLU PP 332 Powder, Tirzepatide Capsules
